TLO - Delayed Quote EUR

Organon & Co. (4OGN.TI)

8.01

+0.06

+(0.81%)

At close: May 6 at 9:40:25 AM GMT+2

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for 4OGN.TI

Why Organon (OGN) Could Beat Earnings Estimates Again

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Organon & Co. (4OGN.TI)

Recent News: 4OGN.TI

Why Organon (OGN) Could Beat Earnings Estimates Again

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Organon Full Year 2024 Earnings: EPS Misses Expectations

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

An excellent week for Organon & Co.'s (NYSE:OGN) institutional owners who own 83% as one-year returns inch higher

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD